Owings Mills, MD, July 03, 2014 --(PR.com
)-- Univec, Inc. (UNVC) a specialty pharmaceutical company, announces the appointment for Chairman of the Financial Advisory Board ("CFAB" or "Chairman") Robert M. Cohen of Revolution Investment Management based in New York. Mr. Cohen will be responsible for overseeing operations in finance. With over 32 years in the investment industry Mr. Cohen was Founder and President of Robert M. Cohen and Co., a full service brokerage firm specializing in investment banking , research and marketing making.
David L. Dalton, President and CEO of Univec stated, “We are delighted to have reached this agreement with such a seasoned professional. Mr. Cohen's expertise will lead the company's financial operations and funding process for expanding and moving forward.”
Univec, Inc. A minority business enterprise (MBE) is a Specialty Pharmaceutical Company that manufactures and distributes transdermal patches and high cost Specialty Pharmaceuticals. Recent NDC approvals by the FDA provides a niche market for smoking cessation, nicotine replacement products and pain management along with behavioral health pharmaceuticals.
Forward Looking Statements
This document may contain forward-looking statements based on current expectations that could be affected by the risks and uncertainties involved in Univec’s business. These risks and uncertainties include, but are not limited to, the risks described from time to time in Univec’s reports to the General Public and reporting agencies. Subsequent written or oral statements attributable to Univec or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements in this document and those in Univec’s reports filed
The Specialty Pharmaceutical Company
David Dalton, President